AcquisitionsJul 7, 2026, 05:17 PM
CareDx Acquires Naveris for $161.8M; Divests Lab Products for $171.7M
AI Summary
CareDx, Inc. completed the acquisition of Naveris, Inc. for $161.8 million in cash, with potential additional payments of up to $100 million based on revenue milestones. This strategic move expands CareDx's leadership into high-growth specialty oncology, increasing its estimated addressable market to over $12 billion. Concurrently, CareDx divested its Lab Products business to Eurobio Scientific for $171.7 million in cash, aiming to sharpen its focus on U.S. precision medicine testing services and patient and digital solutions.
Key Highlights
- CareDx completed the acquisition of Naveris, Inc. for $161.8 million cash.
- Naveris equityholders are eligible for up to $100.0 million in contingent cash consideration.
- Naveris's NavDx test is Medicare-covered for HPV-positive Head & Neck and Anal Cancers.
- Naveris generated approximately $35 million in revenue in 2025, more than doubling YoY.
- CareDx's estimated addressable market expands to over $12 billion.
- CareDx divested its Lab Products business to Eurobio Scientific for $171.7 million cash.
- The divestment includes IVD PCR and NGS-based kits for transplant typing and monitoring.
Price Impact
More from CDNA